Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial

JAMA Oncol. 2023 Feb 1;9(2):275. doi: 10.1001/jamaoncol.2022.6135.

Authors

Aaron J Grossberg¹, Krishan R Jethwa², Susannah G Ellsworth³

Affiliations

¹ Department of Radiation Medicine, Oregon Health & Science University, Portland.
² Department of Radiation Oncology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota.
³ University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.

PMID: 36454560
DOI: 10.1001/jamaoncol.2022.6135

No abstract available

Publication types

Clinical Trial
Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Fluorouracil / therapeutic use
Humans
Neoadjuvant Therapy*
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / radiotherapy

Substances

Fluorouracil